logo

MediciNova Announces Abstract Regarding MN-166 ( ibudilast ) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

  a week ago   
post image
LA JOLLA, Calif., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market ( NASDAQ:MNOV ) and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , today announced that an abstract regarding a clinical trial of ...
Ticker Sentiment Impact
MNOV
Neutral
28 %